Neuroscience Trials Australia
CompanyAustralia
Neuroscience Trials Australia develops one asset, in phase 2 (Triumeq in amyotrophic lateral sclerosis). Mostly small molecule; based in Australia.
- 1
- Asset
- Furthest stage
- Phase 2
- 9
- Trials
- 0
- Signals
Pipeline
1Combines dolutegravir, abacavir and lamivudine to inhibit viral integrase and reverse transcriptase, suppressing retroviral replication.
Phase 2, Small molecule, amyotrophic lateral sclerosis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials10
- Similar companies6